Omeros Corp. Stock
€8.96
Your prediction
Omeros Corp. Stock
Pros and Cons of Omeros Corp. in the next few years
Pros
Cons
Performance of Omeros Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Omeros Corp. | 4.670% | 2.050% | 19.149% | 189.968% | -33.630% | 97.010% | -20.107% |
| Evolus Inc | -1.600% | -9.134% | -6.334% | -31.057% | -0.697% | -19.822% | -43.625% |
| Heron Therapeutics Inc. | -5.130% | 4.509% | 12.025% | -77.799% | -65.045% | -65.842% | -96.487% |
| Rhythm Pharmaceuticals | -1.560% | -5.500% | 22.727% | 25.166% | 1.070% | 575.000% | 505.769% |
Comments
News
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?
Choosing between Heartflow (NASDAQ:HTFL) and Omeros (NASDAQ:OMER) in 2026 requires balancing the rapid revenue growth of an AI diagnostic platform against the high-stakes commercial launch of a new
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
Deciding between NovoCure (NASDAQ:NVCR) and Omeros (NASDAQ:OMER) requires a look at two different stages of medical innovation. Both companies aim to solve difficult health challenges using unique
Omeros Q1 Earnings Call Highlights
Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA


